Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; erythrosine; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; purified talc; sodium lauryl sulfate; purified water; gelatin; titanium dioxide; brilliant blue fcf - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: brilliant blue fcf; pregelatinised maize starch; gelatin; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; purified talc; lactose monohydrate; purified water; titanium dioxide - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: purified talc; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; erythrosine; titanium dioxide; lactose monohydrate; brilliant blue fcf; purified water; sodium lauryl sulfate; gelatin - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pct holdings pty ltd - fluroxypyr as the methyl heptyl ester; n-methylpyrrolidone; liquid hydrocarbon - emulsifiable concentrate - fluroxypyr as the methyl heptyl ester pyridine-pyridinoxy active 400.0 g/l; n-methylpyrrolidone solvent other 100.0 g/l; liquid hydrocarbon solvent other 300.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; calcium hydrogen phosphate dihydrate; purified talc; hypromellose; magnesium stearate; microcrystalline cellulose; hyprolose; titanium dioxide - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: titanium dioxide; calcium hydrogen phosphate dihydrate; purified talc; microcrystalline cellulose; hypromellose; hyprolose; sodium starch glycollate; magnesium stearate - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; calcium hydrogen phosphate dihydrate; purified talc; hypromellose; magnesium stearate; microcrystalline cellulose; hyprolose; titanium dioxide - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: titanium dioxide; calcium hydrogen phosphate dihydrate; purified talc; microcrystalline cellulose; hypromellose; hyprolose; sodium starch glycollate; magnesium stearate - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

farmalinx pty ltd - fluroxypyr as the methyl heptyl ester; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - fluroxypyr as the methyl heptyl ester pyridine-pyridinoxy active 400.0 g/l; n-methyl-2-pyrrolidone solvent other 100.0 g/l; liquid hydrocarbon solvent other 316.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 5 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; (s)-lactic acid - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia